Kalaris Therapeutics Inc (KLRS) Stock

Kalaris Therapeutics Inc (KLRS) is a Healthcare stock trading at $4.15 (as of 2026-08-21), with a market capitalization of $98.79M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

Valuation — source: SEC EDGAR (first-party)
Price$4.15
Market Cap$98.79M
Price / Book1.71
FCF Yield-31.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$5.49M
Net Margin-1071.3%
Revenue Growth (YoY)-4.3%
EPS Growth (YoY)541.0%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderSAMSARA BIOCAPITAL, LLC ($74.71M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOAndrew Oxtoby
Employees14
CountryUS
IPO Date2020-07-30

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Black Diamond Therapeutics, Inc. (BDTX)
  • TScan Therapeutics, Inc. (TCRX)
  • ProKidney Corp. (PROK)
  • Pelthos Therapeutics Inc. (PTHS)
  • Atara Biotherapeutics, Inc. (ATRA)
  • Cognition Therapeutics, Inc. (CGTX)
  • Outlook Therapeutics, Inc. (OTLK)
  • Cardiff Oncology, Inc. (CRDF)
KLRS earnings history · KLRS institutional & insider holders · KLRS KPIs & operating metrics · KLRS financials · KLRS investor presentations & press releases · KLRS SEC filings · KLRS peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.